Study guide

10.2 Youth and Pregnancy

IC&RC Alcohol and Drug Counselor ADC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Applying, Scoring, and Retakes

2 Domain I: Addiction Science

2.1 Neurobiology of Addiction 2.2 Risk Factors for Substance Use Disorders 2.3 Stages and Patterns of Substance Use Disorders

3 Domain I: Pharmacology Foundations

3.1 Drug Classifications, Interactions, and Cross-Tolerance 3.2 Intoxication and Overdose 3.3 Withdrawal Syndromes

4 Domain I: Major Substances

4.1 Alcohol 4.2 Sedative-Hypnotics and Benzodiazepines 4.3 Stimulants 4.4 Opioids

5 Domain I: Other Substances and Co-Occurring Conditions

5.1 Cannabis, Hallucinogens, Dissociatives, Inhalants, and Nicotine 5.2 Physiological, Psychological, and Social Effects 5.3 Co-Occurring Mental Health Conditions 5.4 Co-Occurring Medical Conditions

6 Domain II: Screening and Interviewing

6.1 Assessment Interviewing Techniques 6.2 Motivational Interviewing in Screening and Assessment 6.3 Brief Screening Instruments 6.4 Comprehensive Assessment Instruments

7 Domain II: Diagnosis and History

7.1 Drug and Alcohol Testing 7.2 DSM-5-TR Substance Use Disorder Criteria 7.3 Specifiers, Severity, and Differential Diagnosis 7.4 Biopsychosocial History and Collateral Sources

8 Domain II: Needs and Placement

8.1 Immediate and Ongoing Needs 8.2 ASAM Assessment Dimensions 8.3 ASAM Levels of Care and Placement

9 Domain III: Communication, Rapport, and Crisis

9.1 Communication and Learning Styles 9.2 Building Rapport 9.3 Reviewing Patterns and Methods of Use 9.4 Crisis Response and De-escalation

10 Domain III: Case Management and Populations

10.1 Referrals, Case Management, and Resources 10.2 Youth and Pregnancy 10.3 LGBTQ+, Justice-Involved, and Housing-Insecure Clients 10.4 Multidisciplinary Collaboration and Family Supports

11 Domain III: Trauma, Change, and Treatment Planning

11.1 Trauma and the Client 11.2 Vicarious Trauma and Counselor Burnout 11.3 Ambivalence, Resistance, and Feedback 11.4 Treatment Planning

12 Domain III: Groups, Discharge, and Recovery Pathways

12.1 Group Curriculum and Process 12.2 Group Dynamics and Cohesiveness 12.3 Discharge Planning and Termination 12.4 Multiple Pathways of Recovery including MAT

13 Domain IV: Boundaries and Scope

13.1 Dual Relationships 13.2 Self-Disclosure and Self-Awareness 13.3 Scope of Practice 13.4 Conflicts of Interest

14 Domain IV: Culture, Equity, and Rights

14.1 Multicultural Perspectives 14.2 Diversity, Inclusion, and Equity in Care 14.3 Client and Patient Rights

15 Domain IV: Documentation and Privacy

15.1 Documentation and Record Storage 15.2 42 CFR Part 2 Confidentiality 15.3 HIPAA and Privacy Intersections

16 Domain IV: Consent, Supervision, and Grievances

16.1 Informed Consent 16.2 Supervision and Consultation 16.3 Client Grievances

10.2 Youth and Pregnancy

Key Takeaways Explain This Topic AI

Task III.F includes youth and pregnancy as specific-population concerns: developmental fit, consent and confidentiality, and perinatal medical risk are counseling tasks, not extras.

Adolescent SUD consent and parental access are jurisdiction-specific; 42 CFR Part 2 §2.14 follows state capacity to consent — there is no single federal age such as 16.

If a minor can consent to SUD treatment alone under state law, the minor generally controls Part 2 disclosures, including to parents; mandated child-abuse reporting still applies.

CDC: there is no known safe amount of alcohol, and no safe time, during pregnancy; fetal alcohol spectrum disorders are a lifelong risk from prenatal alcohol exposure.

ACOG and SAMHSA recommend methadone or buprenorphine as first-line medication for opioid use disorder in pregnancy; naltrexone is not typically initiated; neonatal opioid withdrawal is expected and treatable and is not a reason to withhold agonist treatment.

Last updated: September 2026

10.2 Youth and Pregnancy

Quick Answer: Task III.F names youth and pregnancy among specific populations. For adolescents, consent and confidentiality follow state law , then 42 CFR Part 2 minor-patient rules — do not invent a federal age. For pregnancy, no known safe amount of alcohol (CDC), and for opioid use disorder methadone or buprenorphine are first-line; naltrexone is not typically started in pregnancy. Neonatal opioid withdrawal can follow agonist treatment and is not a reason to withhold it.

Independent ADC prep by ExamFinch treats these as counseling-hour skills, not specialty trivia. A 16-year-old and a pregnant 32-year-old can both sit in your caseload this week. The exam item often tests whether you change the plan for development, privacy, or perinatal medicine instead of running an adult mixed-group script.

Adolescent confidentiality and consent traps

There is no single U.S. age at which every minor may independently consent to SUD treatment. Some states allow a young adolescent to consent; others require a parent or guardian. Check the law that governs the session you are in. Promising "nothing ever reaches your parents" is a trap in every jurisdiction, because child-abuse and neglect reporting , duty-to-protect, and medical emergencies still exist.

42 CFR Part 2 §2.14 (minor patients) then layers federal SUD-record rules on top of that state capacity:

State-law starting point Who consents to treatment Who generally controls Part 2 written consent to disclose Trap

Minor may apply for and obtain SUD treatment alone The minor Only the minor , including disclosures to a parent (even for billing) Telling the parent the whole story because "they pay the rent"

State requires parent/guardian consent to treat Parent/guardian plus the minor's participation as required Both the minor and the parent/guardian for Part 2 consents Notifying the parent that the minor even applied, unless the minor consents or a narrow incapacity-and-danger rule applies

If the minor lacks capacity because of extreme youth or a mental or physical condition, and there is a substantial threat to life or physical well-being , the Part 2 program director may disclose facts needed to reduce that threat to a parent or guardian. That is a safety valve , not a standing invitation to brief the household after every group.

School settings can add FERPA when education records are involved. Do not assume a school counselor, a coach, or a parent portal may see Part 2 SUD records because the student is a minor. When in doubt, get the consent the rule actually requires.

Worked trap: A 15-year-old in a state that allows independent SUD consent says, "Don't tell my mom I smoked fentanyl." You can usually keep that out of a parental update. You cannot promise secrecy if they describe current physical-sexual abuse in the home, or if they are about to leave to inject alone tonight and you have a duty to act. Name the limits early , the same way 9.2 named the dual role for court clients.

Developmental issues: not a short adult

Adolescence is a developmental stage , not a smaller dose of adult counseling. Reward sensitivity and peer context often run ahead of prefrontal planning. Identity, autonomy fights with caregivers, school, sleep, and social media are the real setting of use. Adult confrontation ("admit you are an addict or we have nothing to talk about") usually produces discord, not insight.

Developmental fact Counseling implication Wrong application

Peers often outweigh counselor speeches Ask who they use with, who they hide from, who still feels safe A lecture on "bad friends" with no network plan

Family is still a primary system Family-based models (and TIP 39 skills you will reuse in 10.4) are often indicated with proper consent Dumping the chart to parents as if family therapy does not need permission

Abstract relapse lectures bounce Concrete plans: the party Friday, the vape in the bathroom, the ride home A 40-minute adult process group as the default level of care

Screening language differs Youth-adapted screens such as CRAFFT belong in assessment; here you respond to what they mean Using only CAGE wording written for adults

Co-occurring ADHD, trauma, depression are common Refer for psychiatric and school supports; do not treat every fidget as "resistance" Withholding SUD care until a perfect diagnosis arrives

Do not place a 15-year-old in an adult mixed process group as your only offer. If that is all your agency has, that is a III.E referral to a youth program, not a creative use of leftover chairs.

A pregnant adolescent is both populations at once: minor-consent rules and perinatal medicine. Do not skip either.

Pregnancy, FASD, and NAS/NOWS

CDC's current teaching is blunt: there is no known safe amount of alcohol during pregnancy , no safe time , and all types of alcohol (beer, wine, liquor) can harm. Alcohol can pass to the fetus and is associated with miscarriage, stillbirth, preterm birth, SIDS, and fetal alcohol spectrum disorders (FASDs) — lifelong physical, behavioral, and intellectual disabilities. Not every exposed fetus is affected the same way; you cannot pick a "safe" glass because the last pregnancy "went fine." FASD prevention is not drinking alcohol while pregnant or while trying to conceive . Brief intervention plus referral is still counseling; shaming people out of prenatal care is not.

Neonatal abstinence syndrome (NAS) is a broader withdrawal picture in newborns after prenatal exposure to various substances. Neonatal opioid withdrawal syndrome (NOWS) is the opioid-specific term used by the American Academy of Pediatrics. Infants exposed to methadone or buprenorphine may withdraw; ASAM notes withdrawal signs in a substantial share of agonist-exposed newborns (published ranges often span roughly 30–80%). That risk is expected and treatable (rooming-in, feeding support, sometimes medication). Concern for NAS/NOWS alone does not justify withholding medication for opioid use disorder. Untreated OUD in pregnancy carries overdose, relapse, infection, and chaotic prenatal care — worse problems than a monitorable withdrawal syndrome.

Punitive reporting of pregnancy and substance use is state-specific . ACOG has long warned that criminalization drives people away from care. Know whether your jurisdiction requires a child-welfare report for prenatal exposure. Provide treatment either way. Do not invent a national duty to call the police on every pregnant client.

Medication for OUD in pregnancy

ACOG, CDC, and SAMHSA recommend opioid agonist pharmacotherapy — methadone or buprenorphine — with prenatal care and behavioral support, rather than supervised withdrawal as the standard plan. Withdrawal and taper-to-zero are associated with high relapse , which is dangerous for the pregnant person and the fetus. Dose often rises in the third trimester because of metabolism and volume changes; lowering the dose "so the baby will not withdraw" is the usual wrong move.

Medication Pregnancy role Counselor-level facts

Methadone First-line agonist MOUD Still dispensed for OUD through a certified OTP ; counseling plus medical coordination

Buprenorphine First-line agonist MOUD Office-based prescribing follows DEA Schedule III rules after the federal X-waiver ended (MAT Act / Consolidated Appropriations Act, 2023). Some studies associate buprenorphine with less severe NOWS than methadone; both remain acceptable. Combination buprenorphine-naloxone is increasingly treated as acceptable; do not delay care to hunt a historical mono-product if a prescriber is ready

Naltrexone (oral or extended-release) Not typically initiated as first-line OUD treatment in pregnancy Human safety data remain limited . ACOG: if someone is already stable on naltrexone and becomes pregnant, have an individualized discussion of limited safety data versus relapse risk if stopped . Do not treat naltrexone as the default perinatal OUD medicine

The federal X-waiver is gone; methadone for OUD is still an OTP medication . Naloxone for overdose response still belongs in the household plan. Breastfeeding on stable methadone or buprenorphine is often supported when there is no ongoing illicit use and no separate contraindication (for example HIV, depending on current infectious-disease guidance) — coordinate with obstetric and pediatric clinicians rather than inventing a ban.

Worked perinatal item: A 28-year-old at 22 weeks, using fentanyl daily, asks you to "get me off everything so my baby is not born addicted." Accurate counseling: the newborn may have NOWS with methadone or buprenorphine; that is not the same as a baby with a behavioral addiction; stopping agonist treatment now raises relapse and overdose risk; you will warm-handoff to an OTP or a buprenorphine prescriber and prenatal care; you will not start naltrexone as the first perinatal OUD plan.

Exam traps

"Federal law says 16" is not a consent rule.

Parents do not automatically own a minor's Part 2 record when the minor could consent to treatment alone.

A little wine in the third trimester is not a known safe amount.

Stopping methadone to prevent NAS is not first-line perinatal OUD care.

Naltrexone is FDA-approved for OUD in general; that does not make it the typical start medicine in pregnancy.

Loading diagram... Youth consent rules and perinatal OUD decisions in Domain III.F